Neuromyelitis Optica
Conditions
Keywords
Neuromyelitis Optica, NMO, multiple sclerosis (MS), Iatrogeny., Autoimmune diseases
Brief summary
Neuromyelitis Optica (NMO) is a neuroinflammatory disease related to multiple sclerosis (MS). It affects young subjects and causes a lot of handicap without treatment. Thus, aggressive treatments are frequently introduced early in the life of patients and maintained over the long term. A long duration of treatment exposes to iatrogenism. Therapeutic de-escalation trials in MS or other autoimmune diseases show rebound phenomena. In the NMO, there are no published data on the tolerance of desescalations to guide such strategies.
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Major patients who have received long-term treatment for NMO * Patients with a prospectively diagnosed NMO using the 2015 NMO classification criteria (IPND) * Patients who retrospectively meet the classification criteria of the 2015 NMO (IPND) * Patients who have not expressed their opposition, after information, to the reuse of their data for research purposes.
Exclusion criteria
* Patient who expressed his opposition to participating in the study * Lack of data on the assay of anti-AQP4 and anti-MOG antibodies * Less than a year of taking a second-line treatment before the relay * End of follow-up \<1 year following the transfer, this therefore includes patients whose transfer took place less than one year before the date of data extraction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Retrospective evaluation of the risk of rebound during therapeutic escalations in neuromyelitis optica (NMO) | Files analysed retrospectively from January 01, 2000 to December 31, 2020 will be examined] |
Countries
France
Outcome results
None listed